Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIb single-arm study of giredestrant adherence, tolerability, and patient-reported outcomes in ER-positive/HER2-negative early breast cancer
CTR20263912Phase 3Active
- Sponsor
- Roche
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of giredestrant in breast cancer, sponsored by Roche. Started Oct 2026; status: active.
02
Drugs
giredestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20263912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263912.